Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 1
2005 2
2006 1
2007 2
2008 5
2009 1
2010 4
2011 5
2012 4
2013 3
2014 3
2015 4
2016 3
2017 1
2018 4
2019 6
2020 6
2021 10
2022 12
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

67 results
Results by year
Filters applied: . Clear all
Page 1
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Bakris GL, et al. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. N Engl J Med. 2020. PMID: 33264825 Clinical Trial.
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Pitt B, et al. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28. N Engl J Med. 2021. PMID: 34449181 Clinical Trial.
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Bakris GL, et al. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25. Am J Nephrol. 2019. PMID: 31655812 Free PMC article. Clinical Trial.
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R; FIDELIO-DKD and FIGARO-DKD Investigators. Rossing P, et al. Diabetes Care. 2022 Dec 1;45(12):2991-2998. doi: 10.2337/dc22-0294. Diabetes Care. 2022. PMID: 35972218 Free PMC article. Clinical Trial.
Splenic lymphangioma.
Ioannidis I, Kahn AG. Ioannidis I, et al. Arch Pathol Lab Med. 2015 Feb;139(2):278-82. doi: 10.5858/arpa.2013-0656-RS. Arch Pathol Lab Med. 2015. PMID: 25611113 Free article. Review.
Metabolic effects of renal denervation.
Thomopoulos C, Spanoudi F, Kyriazis I, Anastasopoulos I, Ioannidis I. Thomopoulos C, et al. Among authors: ioannidis i. Curr Clin Pharmacol. 2013 Aug;8(3):206-11. doi: 10.2174/1574884711308030006. Curr Clin Pharmacol. 2013. PMID: 23173965 Review.
The road from obesity to type 2 diabetes.
Ioannidis I. Ioannidis I. Angiology. 2008 Apr-May;59(2 Suppl):39S-43S. doi: 10.1177/0003319708318583. Epub 2008 May 27. Angiology. 2008. PMID: 18505743 Review.
Atypical Type II Endoleak After EVAR: the Left Behind Artery.
Paraskevas N, Ioannidis I. Paraskevas N, et al. Among authors: ioannidis i. Eur J Vasc Endovasc Surg. 2022 Oct;64(4):348. doi: 10.1016/j.ejvs.2022.07.041. Epub 2022 Aug 5. Eur J Vasc Endovasc Surg. 2022. PMID: 35934223 No abstract available.
67 results